Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial

Siow Ming Lee; Penella J Woll; Robin Rudd; David Ferry; Mary O'Brien; Gary Middleton; Stephen Spiro; Lindsay James; Kulsam Ali; Mark Jitlal; Allan Hackshaw

doi:10.1093/jnci/djp200

Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial

Siow Ming Lee, Penella J Woll, Robin Rudd, David Ferry, Mary O'Brien, Gary Middleton, Stephen Spiro, Lindsay James, Kulsam Ali, Mark Jitlal, Allan Hackshaw

Cancer and Genomic Sciences

Research output: Contribution to journal › Article › peer-review

105 Citations (Scopus)

Abstract

Cancer cells rely on angiogenesis for growth and dissemination, and small cell lung cancer (SCLC) is a highly angiogenic tumor. We evaluated thalidomide, an anti-angiogenic agent, when combined with chemotherapy and as maintenance treatment.

Original language	English
Pages (from-to)	1049-57
Number of pages	9
Journal	Journal of the National Cancer Institute
Volume	101
Issue number	15
DOIs	https://doi.org/10.1093/jnci/djp200
Publication status	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jnci/djp200

Cite this

Lee, S. M., Woll, P. J., Rudd, R., Ferry, D., O'Brien, M., Middleton, G., Spiro, S., James, L., Ali, K., Jitlal, M., & Hackshaw, A. (2009). Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. Journal of the National Cancer Institute, 101(15), 1049-57. https://doi.org/10.1093/jnci/djp200

@article{ccc74aa27f24460e84de15fc3e65f54e,

title = "Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial",

abstract = "Cancer cells rely on angiogenesis for growth and dissemination, and small cell lung cancer (SCLC) is a highly angiogenic tumor. We evaluated thalidomide, an anti-angiogenic agent, when combined with chemotherapy and as maintenance treatment.",

author = "Lee, {Siow Ming} and Woll, {Penella J} and Robin Rudd and David Ferry and Mary O'Brien and Gary Middleton and Stephen Spiro and Lindsay James and Kulsam Ali and Mark Jitlal and Allan Hackshaw",

year = "2009",

doi = "10.1093/jnci/djp200",

language = "English",

volume = "101",

pages = "1049--57",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "15",

}

Lee, SM, Woll, PJ, Rudd, R, Ferry, D, O'Brien, M, Middleton, G, Spiro, S, James, L, Ali, K, Jitlal, M & Hackshaw, A 2009, 'Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial', Journal of the National Cancer Institute, vol. 101, no. 15, pp. 1049-57. https://doi.org/10.1093/jnci/djp200

TY - JOUR

T1 - Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer

T2 - a randomized, double-blind, placebo-controlled trial

AU - Lee, Siow Ming

AU - Woll, Penella J

AU - Rudd, Robin

AU - Ferry, David

AU - O'Brien, Mary

AU - Middleton, Gary

AU - Spiro, Stephen

AU - James, Lindsay

AU - Ali, Kulsam

AU - Jitlal, Mark

AU - Hackshaw, Allan

PY - 2009

Y1 - 2009

N2 - Cancer cells rely on angiogenesis for growth and dissemination, and small cell lung cancer (SCLC) is a highly angiogenic tumor. We evaluated thalidomide, an anti-angiogenic agent, when combined with chemotherapy and as maintenance treatment.

AB - Cancer cells rely on angiogenesis for growth and dissemination, and small cell lung cancer (SCLC) is a highly angiogenic tumor. We evaluated thalidomide, an anti-angiogenic agent, when combined with chemotherapy and as maintenance treatment.

U2 - 10.1093/jnci/djp200

DO - 10.1093/jnci/djp200

M3 - Article

C2 - 19608997

SN - 0027-8874

VL - 101

SP - 1049

EP - 1057

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

IS - 15

ER -

Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this